News | May 06, 2025
Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25, 50, 100 and 200 mg tablets
Topiramate is indicated as a treatment of epilepsy and migraine
Topiramate is indicated as a treatment of epilepsy and migraine
Topiramate is the generic version of Supernus Pharmaceuticals’ Trokendi XR
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Topiramate Extended-Release capsule had annual sales of US $68.8 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022)
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Subscribe To Our Newsletter & Stay Updated
